Mycophenolate mofetil (MMF, CellCept®) is a prodrug of mycophenolic acid (MPA), an
inhibitor of inosine monophosphate dehydrogenase (IMPDH). This is the rate-limiting …

Among natural products, one microbial metabolites penicillinsstands above all others for its
profound influence on human lives. The development of penicillin by Howard Florey and his …

Minimal-change disease (MCD) counts for 10 to 15% of cases of primary nephrotic
syndrome in adults. Few series have examined this disease in adults. A retrospective review …

Primary focal segmental glomerulosclerosis (FSGS) is a disease with poor prognosis and
high unmet therapeutic need. Here, we evaluated the safety and pharmacokinetics of single …

Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-
controlled randomized study. Background Because humoral immunity is believed to play a …

Mycophenolate mofetil treatment for primary glomerular diseases. Background Treatment of
primary glomerular diseases may be unsuccessful or have potential toxicities. Therefore, we …

Since the efficacy of mycophenolate mofetil (MMF) to treat immunoglobulin A (IgA)
nephropathy is controversial, we extended our original study by following 40 Chinese …

Background: The aim of the present study was to evaluate the efficacy of mycophenolate
mofetil in the induction therapy of proliferative lupus nephritis. Methods: Forty‐four patients …

It is currently being debated whether pharmacokinetic monitoring of mycophenolic acid
(MPA), the active constituent of mycophenolate mofetil (MMF), can optimize MMF therapy …

Minimal change disease (MCD) is the etiology of 10%–25% of cases of nephrotic syndrome
in adults. The mainstay of treatment for adult MCD, oral gucocorticoids, is based on two …